VJHemOnc public
[search 0]
More

Download the App!

show episodes
 
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and r ...
 
Loading …
show series
 
The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of trainees in the field of bone marrow transplant and cellular therapy and provide advice and support for trainees. The group, composed of trainees, young investigators, and students, wants to encourage trainees to establis…
 
The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal amyloid fibrils made up of immunoglobulin light chains. These insoluble fibrils deposit extracellularly and accumulate within organs such as the heart, kidneys, liver, spleen, nervous system, and digestive t…
 
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and showcased the latest advances in the field of transplantation and cellular therapies. VJHemOnc is joined by Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, who chaired an insightful discussion on the …
 
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and showcased the latest advances in the field of transplantation and cellular therapies. VJHemOnc is joined by Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, who chaired an insightful discussion on the …
 
Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be diagnosed per year in the US alone. According to the NIH, 27.4% of people diagnosed with AML will survive for five years or more. AML is typically treated with a combination of cytarabine and anthracycline-based chemotherapy regimens, …
 
Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be diagnosed per year in the US alone. According to the NIH, 27.4% of people diagnosed with AML will survive for five years or more. AML is typically treated with a combination of cytarabine and anthracycline-based chemotherapy regimens, …
 
Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America. CLL progresses slowly and is generally incurable, with the majority of patients showing relapse and having short remissions. Over the past decade, there has been a dramatic increase in our understanding of the pathogenesis o…
 
Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for lymphoma are not yet well-characterized and treatment depends on the type of lymphoma, it’s location and stage. Recent developments in the treatment of lymphoma include research into novel chemotherapy regimens, chimeric antige…
 
The diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the globe, pioneers in the recognition and understanding of MDS pulled together to collaborate and push forward this research laying the foundations of where we are today. VJHemOnc were delighted to catch up with four of th…
 
The armamentarium of therapeutic modalities in acute myeloid leukemia (AML) has taken several strides in the last few years as a result of a greater understanding of the genomic landscape disease as well as how resistance to conventional therapies can develop. At the virtual 62nd American Society of Hematology 2020 Annual Meeting and Exposition (AS…
 
The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European Haematology Association (EHA), and shed light on the current and future indications of CAR T-cell therapies in hematological oncology. The nursing program highlighted key questions in the management of patients treate…
 
Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm, resulting in significant improvements in patient outcomes. Despite advances in treatment and outcomes, multiple myeloma is still considered an incurable disease. The management of newly diagnosed…
 
Mechanistically, myeloproliferative neoplasms (MPNs), comprising primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), were a mystery for many decades. The breakthrough discovery of near-universal upregulation of the JAK-STAT signaling pathway as the driving force in MPNs triggered a wave of research that has drasti…
 
During the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition, several abstracts provided important updates for the management of myelodysplastic syndromes (MDS), including clinical trial data for emerging therapeutic options for MDS. In this podcast, we hear from three leading experts in MDS, who discuss the key updates p…
 
Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm for this disease. New therapies and drug approvals have improved outcomes for patients, and in those not eligible for standard induction chemotherapy followed by transplantation, lower-intensity therap…
 
The epidemiology, diagnosis and treatment of myelodysplastic syndromes (MDS)varies across the globe. In resource-limited countries, the diagnosis of MDS canbe challenging – and databases with up-to-date information on the epidemiologyof MDS is also not always available. Access to the latest technologies fordiagnosis and treatment of patients can al…
 
Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble protein. Amyloid forms when protein misfolding transforms soluble precursor proteins into insoluble amyloid fibrils. Amyloid fibrils can disseminate systemically and deposition on organs causes disturbance of organ f…
 
Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically immature lymphocytes in the bone marrow, blood and lymphatic tissue. CLL is the most common type of leukemia. It develops very slowly and is generally incurable, with relapses often occurring a…
 
The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of the disease leading to an improvement in patients outcomes. Despite vast advances, the clinical management of patients with multiple myeloma remains challenging, namely resistance in relapsed patients as well as the identification o…
 
Lymphoma is a group of malignant neoplasms of lymphocytes that progress in the lymphatic system. Generally, lymphomas are categorized into two groups: non-Hodgkin lymphoma and Hodgkin lymphoma. Depending on which type of lymphocyte is affected, NHL is classified into B-cell and T-cell NHL. The treatment landscape of B-cell NHL has evolved with the …
 
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of rare myeloid neoplasms characterized by the abnormal proliferation of hematopoietic stem cells within one or more terminal myeloid lineages. Recent advances in the field have drastically improved our understanding of the pathophysiology of MPNs, which have expanded the scope for poten…
 
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute myeloid leukemia. Patients with lower-risk MDS are defined as having a risk of very low, low, or intermediate disease according to the IPSS-R. The armamentarium of treatment approaches is broadening i…
 
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are seen in 30% of all acute myeloid leukemia (AML) cases, most commonly involving the internal tandem duplication region (FLT3-ITD) which constitutively activate its kinase activity and thus, allows for leukemia cell proliferation and survival. A particularly poor prognosis is conferred by mu…
 
This year’s virtual International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlighted key progress in our understanding of various non-Hodgkin lymphoma (NHL) subtypes, the role of the immune microenvironment, as well as evaluating novel therapeutic strategies in development for patients with NHL. In this podcast, John Gribben, MD, DSc, FRCP, FRCPa…
 
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute myeloid leukemia. With hematopoietic stem cell transplantation representing the only curative option for patients with MDS, the field has not seen the rapid evolution in treatments witnessed in other …
 
The BCL-2 inhibitor venetoclax has been evaluated in many hematological malignancies, including acute myeloid leukemia (AML). More recently, emerging mechanisms of resistance and future directions of venetoclax in combination with hypomethylating agents and IDH inhibitors have been evaluated and data presented at EHA 2020, as well as SOHO 2020 has …
 
IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH targeting agents has shown favorable clinical responses in AML, with ivosidenib and enasidenib (IDH1 and IDH2 inhibitors) being approved by the US F.D.A for relapsed/refractory AML patients. In this podcast, Amir Fathi of Massachusetts General Hospital, Bos…
 
The field of acute myeloid leukemia (AML) has seen rapid progression in the field of immuno-oncology which has led to vast improvements in patient outcomes. The annual Society of Hematological Oncology (SOHO) allowed great discussion of the translation of key data into clinical practice, including the state of the art in immunotherapy for AML. In t…
 
Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease is the most recognized complication post-HSCT and involves a reaction of donor immune cells against host tissues. Lately, HSCTs have been impacted in the context of the coronavirus disease (COVID-19).…
 
Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is a popular form of cell therapy, specifically immunotherapy, that can use a patient’s own altered immune cells to fight cancer. In this podcast, Annalisa Ruggeri, MD, of IRCCS Ospedale Pediatrico Bambino Gesu, Noopur Raje, MD, of…
 
The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated the community on the latest data and hot topics in the treatment and management of hematological malignancies. The next questions session at SOHO 2020 illuminated important future considerations in man…
 
Recent clinical trials studying novel therapeutic strategies to target chronic lymphocytic leukemia (CLL) have brought a spotlight to their potential as alternatives to traditional chemotherapy. Here we bring you an overview and discussion on the latest trial updates, including CLL12, CLL14, RESONATE, ASCEND, among others. This podcast features Pat…
 
Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more myeloid lineage with largely intact cellular differentiation. Recent advances in the field, such as the detection of new driver mutations and a better understanding of the molecular pathogenesis of MPNs, have …
 
Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with almost 20,000 new cases reported in the US in 2020. With the identification of recurrent mutations and the development of novel agents, stratification has allowed for improvements in patient outcomes. In this podcast, Thomas Cluzeau, MD, PhD, of the Central Uni…
 
Lymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin lymphoma which is the 7th most common cancer type in the US and UK, and conversely, Hodgkin lymphoma which constitutes 0.5-1% of all cancers reported in the US and UK. Treatment strategies depend on the type of l…
 
Patients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high importance. Several strategies have been employed to reduce the risk of infection, whilst still providing appropriate therapies for high-risk patients. In this podcast, Paul Richardson…
 
Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the bone marrow, lymphatic tissue and blood. CLL generally affects the older population and is incurable, however, several novel treatment approaches have developed to improve outcomes of patients…
 
It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been significant advances in the understanding of MPNs, including underlying genetic changes that drive the development of MPNs. This has led to research focusing on targeted therapy and increased the availability of new treat…
 
A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of innovative therapies which has generated rapid progress in the management of CLL. In this podcast, John Gribben of Barts Cancer Institute, London, UK, chairs an insightful discussion with Barbara Eichhorst of the Univer…
 
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer... The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.…
 
The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment... The post The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML appeared first on VJHemOnc.By VJHemOnc
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login